



## ANZGOG Publications – 2005 to 2016

2016		
1.	Rungruang, B. J., Miller, A., Krivak, T. C., Horowitz, N. S., Rodriguez, N., Hamilton, C. A., Backes, F. J., Carson, L. F., Friedlander, M., Mutch, D. G., Goodheart, M. J., Tewari, K. S., Wenham, R. M., Bookman, M. A., Maxwell, G. L. and Richard, S. D. (2016), What is the role of retroperitoneal exploration in optimally debulked stage IIIc epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> . doi:10.1002/cncr.30414	
2.	M. K. Wilson, E. Pujade-Lauraine, D. Aoki, M. R. Mirza, D. Lorusso, A. M. Oza, A. du Bois, I. Vergote, A. Reuss, M. Bacon, M. Friedlander, D. Rincon, F. Joly, S. - J. Chang, A. M. Ferrero, R. J. Edmondson, P. Wimberger, J. Maenpaa, D. Gaffney, R. Zhang, A. Okamoto, G. Stuart, K. Ochiai, on behalf of the participants of the 5th Ovarian Cancer Consensus Conference; 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease. <i>Ann Oncol</i> 2016 mdw663. doi: 10.1093/annonc/mdw663	
3.	Blinman P, Mileshekin L, Khaw P, Goss G, Johnson C, Capp A, Brooks S, Wain G, Kolodziej I, Veillard AS, O'Connell R, Creutzberg CL, Stockler MR. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> 2016.	PORTEC-3
4.	Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshekin L, Creutzberg CL, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> 2016; 60(4): 554-559.	PORTEC-3
5.	Martyn J, Roncolato F, Willson ML, Lindemann K, Mileshekin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. <i>Cochrane Database of Systematic Reviews</i> 2016; 2016(4): CD012160.	
6.	Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. <i>BMC Medical Ethics</i> 2016; 17(1): 63.	AGO-OVAR 16
7.	Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. <i>BMC Cancer</i> 2016; 16(1): 596.	
2015		
1.	DiSipio, Tracey, <b>Janda, Monika, Hayes, Sandra C.</b> , Reul-Hirche, Hildegard, Ward, Leigh, & <b>Obermair, Andreas</b> (2015). The Lymphedema Evaluation in Gynecological cancer Study (LEGS): Design of a prospective, longitudinal, cohort study. <i>Cancer Research Frontiers</i> , 1(1), pp. 104-118.	ANZGOG0901
2.	Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, <b>Beale P</b> , Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, <b>Quinn M</b> , Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncol</i> . 2015 Aug;16(8):928-36.	ICON7
	Gaffney Dk, Suneja G, Ryu Sy, McCormick M, Plante M, Mileshekin L, Small W Jr, Bacon M, Stuart G, Kitchener H. The Cervix Cancer Research Network: A Global Outreach Effort On Behalf Of The Gynecologic Cancer Intergroup. <i>Int J Radiat Oncol Biol Phys</i> . 2015 Jul 1;92(3):506-8.	N/A
3.	Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation	EORTC 55041 Tarceva

	for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), <b>Australia New Zealand Gynaecological Oncology Group (ANZGOG)</b> , and the Mario Negri Gynecologic Oncology group (MaNGO). Epidermal Growth Factor <b>Receptor</b> (EGFR) pathway biomarkers in the randomized phase III trial of erlotinib versus observation in ovarian cancer patients with no evidence of disease progression after first-line platinum-based Chemotherapy. Target Oncol. 2015 May 26. [Epub ahead of print]	
4.	Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, <b>Friedlander M</b> , Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol. 2015 Jan;136(1):37-42.	OVAR 16
5.	Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, <b>Mileshkin L, Pollock PM</b> , Smit VT, Creutzberg CL. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.	PORTEC-3?
6.	Peterlongo P, ....., <b>Friedlander ML</b> , ..... Chenevix-Trench G; KConFab Investigators, Antoniou AC, Friedman E. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16. doi: 10.1158/1055-9965.EPI-14-0532. Epub 2014 Oct 21.	GOG199
7.	<b>Lee CK</b> , Lord S, Grunewald T, <b>Gebbski V</b> , Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, <b>Friedlander M</b> . Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2.	CALYPSO
8.	Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, <b>Vasey P</b> , Pujade-Lauraine E, Gladiéff L, Ferrero A. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.	CALYPSO
<b>2014</b>		
1.	Grimison PS, <b>MR Stockler</b> , M Chatfield, DB Thomson, <b>V Gebbski, M Friedlander</b> , AL Boland, B Houghton, H Gurney, M Rosenthal, N Singhal, G Kichenadasse, SS Wong, CR Lewis, PA Vasey, GC Toner. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Ann Oncol. 2014 Jan;25(1):143-8. (Cobadged ANZGOG0603)	Accelerated BEP
2.	Osorio A, Milne RL, Kuchenbaecker K, .... <b>Tucker K</b> , .....Chenevix-Trench G, Antoniou AC, Benitez J. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 Apr10(4)e1004256. (GOG199 data)	GOG199
3.	<b>King MT, MR Stockler, P Butow, R O'Connell</b> , M Voysey, AM Oza, <b>K Gillies</b> , HS Donovan, R Mercieca-Bebber, <b>J Martyn, K Sjoquist</b> , and <b>ML Friedlander</b> . Development of the Measure of Ovarian Symptoms and Treatment concerns (MOST): aiming for optimal measurement of patient reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer. 2014 Jun;24(5):865-73.	Symptom Benefit
4.	<b>Friedlander ML, MR Stockler, R O'Connell</b> , M Voysey, AM Oza, <b>K Gillies</b> , HS Donovan, <b>J Martyn, K Sjoquist, P Butow</b> . Symptom Benefit Study Group and MT King. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer- a reality check! Results of Stage 1 of GCIG Symptom Benefit Study. Int J Gynecol Cancer. 2014 Jun;24(5):857-64.	Symptom Benefit
5.	<b>Lee CK</b> , Lord S, Grunewald T, <b>Gebbski V</b> , Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, <b>Friedlander M</b> . Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecol Oncol. 2014 Oct 2. pii: S0090-8258(14)01344-4. [Epub ahead of print]	CALYPSO

6.	du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, <b>Friedlander M</b> , Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. <i>J Clin Oncol</i> . 2014 Oct 20;32(30):3374-82.	OVAR-16
7.	Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. <i>J Clin Oncol</i> . 2014 Oct 10;32(29):3275-83. [GOG199 results, no ANZGOG author]	GOG199
8.	Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Cervical Adenocarcinoma. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S96-S101.	N/A
9.	Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S90-5.	N/A
10.	Gourley C, Farley J, Provencher DM, Pignata S, Mileskin L, Harter P, Maenpaa J, Kim JW, Pujade-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S9-S13.	N/A
11.	Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Uterine Serous Carcinoma. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S83-9.	N/A
12.	Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S78-82.	N/A
13.	Pautier P, Ji Nam E, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIg) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S73-7.	N/A
14.	Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIg) Consensus Review: Uterine and Ovarian Leiomyosarcomas. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S61-6.	N/A
15.	Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Uterine and Ovarian Carcinosarcoma. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S55-60.	N/A
16.	Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S5-8.	N/A
17.	Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Germ Cell Tumors. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S48-54.	N/A
18.	Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Sex Cord Stromal Tumors. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl	N/A

	3):S42-7.	
19.	Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Carcinoid Tumors of the Ovary. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S35-41.	N/A
20.	Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Small Cell Cancers. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S30-4.	N/A
21.	Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzazanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Clear Cell Carcinoma of the Ovary. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S20-5.	N/A
22.	Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Mucinous Ovarian Carcinoma. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S14-9.	N/A
23.	Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileskin L, Avall-Lundqvist E, Pautier P, Reed NS, Fujiwara K. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Small Cell Carcinoma of the Cervix. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S102-8.	N/A
24.	Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, Avall-Lundqvist E, Kim K, Freyer G. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Vulvovaginal Melanomas. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9 Suppl 3):S117-22.	N/A
25.	Joly F, McAlpine J, Nout R, Avall-Lundqvist E, Shash E, Friedlander M; Gynaecologic Cancer InterGroup (GCIg). Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action! <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9):1693-9.	N/A
26.	McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F; Gynecologic Cancer InterGroup (GCIg). Quality of Life Research in Endometrial Cancer: What Is Needed to Advance Progress in This Disease Site? Methodological Considerations From the Gynecologic Cancer InterGroup Symptom Benefit Working Group Brainstorming Session, Leiden 2012. <i>Int J Gynecol Cancer</i> . 2014 Nov;24(9):1686-92.	N/A
27.	Amant F, Floquet M, Friedlander G, Kristensen S, Mahner E, Eun ji Nam, MA Powell, I Ray-Coquard, N Siddiqui, P Sykes, AM Westermann and B Seddon. GCIg (Gynecological Cancer Inter Group) Consensus Review for Endometrial Stromal Sarcoma. <i>Int J Gynecol Cancer</i> 2014 (epub ahead of print).	N/A
<b>2013</b>		
1.	Vergote I, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, <b>Steer C</b> , Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, <b>Buck M</b> , Ray-Coquard I, Ferrero A, Favier L, Reed N, Curé H, Pujade-Lauraine E. Randomised phase III study of erlotinib versus 1 observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. An EORTC-GCG and Gynecological Cancer Intergroup study. <i>Journal of Clinical Oncology</i> . Published ahead of print on December 23, 2013 as 10.1200/JCO.2013.50.5669	EORTC 55041 Tarceva
2.	<b>Sjoquist KM, Friedlander ML</b> , O'Connell RL, Voysey M, <b>King MT, Stockler MR</b> , Oza AM, <b>Gillies K, Martyn JK, Butow PN</b> Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. <i>Oncologist</i> . 2013 Oct 9. [Epub ahead of print] PMID: 24107972	Symptom Benefit
3.	<b>Schofield P</b> , Juraskova I, Bergin R, Gough K, <b>Mileskin L</b> , Krishnasamy M, White K, <b>Bernshaw D</b> , Penberthy S, Aranda S. A nurse and peer led support program to assist women in gynaecological oncology, the PeNTAGOn study (Peer and Nurse support Trial to Assist women in Gynaecological Oncology): protocol for a randomised controlled trial. <i>Trials</i> 2013, 14:39. DOI: 10.1186/1745-6215-14-39 (online publication, 11 February 2013).	PeNTAGOn

4.	Price M, Bell M, , <b>Sommeijer DW, Friedlander M, Stockler MR; deFazio A; Webb PM</b> , The Australian Ovarian Cancer Study Group, The Australian Ovarian Cancer Study - Quality of Life, <b>Phyllis N Butow</b> . Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life. <i>Gynecol Oncol</i> . 2013 Jul;130(1):162-8.	Symptom Benefit?
5.	<b>Michael Friedlander</b> and <b>Madeleine King</b> . Patient reported outcomes in ovarian cancer clinical trials. <i>Annals of Oncology (accepted for publication)</i>	Symptom Benefit?
6.	<b>Friedlander ML, Stockler MR, Butow P, King MT</b> , McAlpine J, Tinker A, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? <i>J Clin Oncol</i> . 2013 Jun 20;31(18):2362.	Symptom Benefit?
7.	<b>Blinman P, Gainford C, Donoghoe M , Martyn J, Blomfield P, Grant P, Kichenadasse V, Vaughan M, Brand A, Shannon K, GebSKI V, Stockler MR, Friedlander M</b> . Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG Study. <i>Journal of Gynecol Oncol</i> 2013 Oct;24(4):359-66	TRIPOD
8.	<b>C. K. Lee, R. J. Simes, C. Brown, V. GebSKI</b> , J. Pfisterer, A-M. Swart, D. Berton-Rigaud, M. Plante, T. Skeie-Jensen, I. Vergote, C. Schauer, C. Pisano, G. Parma, K. Baumann, J. A. Ledermann, E. Pujade-Lauraine, J. Bentley, G. Kristensen, A. Belau, M. Nankivell, U. Canzler, S. J. Lor1, C. Kurzeder & <b>M. Friedlander</b> . A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Ann Oncol (2013) 24 (4): 937-943</i>	CALYPSO
9.	Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, <b>Goss G</b> , Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, <b>Vasey P</b> , Kaye SB. A multicenter, randomized trial of flat dosing versus inpatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and <b>ANZGOG</b> study on behalf of GCIg. <i>Ann Oncol (2013) 24 (3): 679-687</i>	SCOTROC4
10.	Couch FJ, Wang X, McGuffog L, Lee A, Olsword C, ..... <b>Friedlander M</b> ,.....Chenevix-Trench G, Antoniou AC; CIMBA. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genet</i> . 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.	GOG199
11.	Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, <b>Stockler M</b> , Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, <b>Beale P</b> , Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncol</i> . 2013 Mar;14(3):236-43. doi: 10.1016/S1470-2045(12)70567-3. Epub 2013 Jan 18.	ICON7
12.	You B, Colomban O, Heywood M, <b>Lee C</b> , Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Rienthaller A, Pujade-Lauraine E, Oza A. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIg study). <i>Gynecologic Oncology</i> 2013; 130(2): 289–294.	CALYPSO
13.	<b>Sommeijer DW, Sjoquist KM, Friedlander M</b> . Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. <i>Current Oncology Reports</i> 2013; 15(541–548).	<b>PARAGON</b>
<b>2012</b>		
1.	Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., <b>GebSKI, V.</b> , Wolfram, G., Reed, N., Pignata, S., Ferrero, A., <b>Brown, C.</b> , Eisenhauer, E., and Pujade-Lauraine, E. (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer -results from the CALYPSO trial, <i>Ann Oncol</i> (2012) 23 (8): 2020-2027	CALYPSO
2.	<b>Tang, A., Kondalsamy-Chennakesavan, S.</b> , Ngan, H., Zusterzeel, P., <b>Quinn, M., Carter, J., Leung, Y., and Obermair, A.</b> (2012) Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801), <i>Gynecol Oncol</i> 126, 36-40.	ANZGOG0801
3.	Wagner, U., Marth, C., Largillier, R., Kaern, J., <b>Brown, C.</b> , Heywood, M., <b>Bonaventura, T.</b> , Vergote, I., Piccirillo, M. C., Fossati, R., <b>GebSKI, V.</b> , and Lauraine, E. P. (2012) Final overall survival results of phase III GCIg CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients, <i>Br J Cancer</i> 107, 588-591.	CALYPSO

4.	Alexandre, J., <b>Brown, C.</b> , Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J., Chalchal, H., <b>Fitzharris, B.</b> , Volgger, B., Vergote, I., Pisano, C., Ferrero, A., and Pujade-Lauraine, E. (2012) CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIg CALYPSO trial, <i>Br J Cancer</i> 106, 633-637.	CALYPSO
5.	Gladieff, L., Ferrero, A., De Rauglaudre, G., <b>Brown, C.</b> , <b>Vasey, P.</b> , Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S. (2012) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial, <i>Ann Oncol</i> 23, 1185-1189.	CALYPSO
6.	Viswanathan, A. N., Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., <b>Narayan, K.</b> , Reed, N., Long, H., Kim, H. J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., Jr., and Trimble, E. (2012) International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIg), <i>Int J Radiat Oncol Biol Phys</i> 82, 250-255.	N/A
7.	Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB,..... <b>Phillips K</b> , ...Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiol Biomarkers Prev.</i> 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.	GOG199
8.	Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, ..... <b>Phillips KA</b> , ....., Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Hum Mutat.</i> 2012 Apr;33(4):690-702. doi: 10.1002/humu.22025. Epub 2012 Feb 14.	GOG199
9.	Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X,... <b>Kirk J</b> , .....Chenevix-Trench G, Couch FJ, Simard J, Easton DF; CIMBA, SWE-BRCA; HEBON; EMBRACE; GEMO Collaborators Study; kConFab Investigators. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Res.</i> 2012 Feb 20;14(1):R33.	GOG199
<b>2011</b>		
1.	<b>Brand A.</b> 2011 Ovarian Cancer Debulking Surgery: A Survey of Practice in Australia and New Zealand. <i>Int J Gynecol Cancer.</i> 2011 21;Feb(2):230-235. IF: 1.733	N/A
2.	<b>Friedlander M</b> , Trimble T, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, <b>Beale P</b> , Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim J, W, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC. Clinical trials in recurrent ovarian cancer. <i>Int J Gynecol Cancer.</i> 2011 May;21(4):750-5.	N/A
3.	Joly F, Ray-Coquard I, Fabbro M, <b>Donoghoe M</b> , Boman K, Sugimoto A, <b>Vaughan M</b> , Reinthaller A, Vergote I, Ferrandina G, Dell'anna T, Huober J, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIg CALYPSO relapsing ovarian cancer trial. <i>Gynecol Oncol.</i> 2011 Aug;122(2):226-32. IF: 3.760	CALYPSO
4.	Kurtz JE, Kaminsky MC, Floquet A, <b>Veillard AS</b> , Kimmig R, Dorum A, Elit L, <b>Buck M</b> , Petru E, Reed N, Scambia G, Varsellona N, <b>Brown C</b> , Pujade-Lauraine E. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIg) CALYPSO sub-study. <i>Ann Oncol.</i> 2011 22;Mar(11) 2417-2423. IF: 6.452	CALYPSO
5.	<b>Lee CK</b> , Gurney H, <b>Brown C</b> , Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, <b>GebSKI V</b> , Pujade-Lauraine E, <b>Lord S</b> , <b>Simes RJ</b> , <b>Friedlander M</b> . Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>Br J Cancer.</i> 2011 Jul 26;105(3):360-5. IF: 4.831	CALYPSO
6.	<b>Lee CK</b> , <b>Simes RJ</b> , <b>Brown C</b> , <b>Lord S</b> , Wagner U, Plante M, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Br J Cancer.</i> 2011 Oct 11;105(8):1144-50. IF: 4.831	CALYPSO
7.	<b>Lee CK</b> , <b>Friedlander M</b> , <b>Brown C</b> , <b>GebSKI VJ</b> , Georgouloupoulos A, Vergote I, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. <i>J</i>	CALYPSO

	Natl Cancer Inst. 2011 Sep 7;103(17):1338-42. IF:14.697	
8.	Perren T, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, <b>Beale P</b> , Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Sell F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK and Oza AM. (2011) A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med 365;Dec(26), 2484-2496.	ICON7
9.	Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, <b>Quinn M</b> , Thigpen T, du Bois A, Kristensen G, Jakobsen A, Dagea S, Greven K, Pamar M, <b>Friedlander M</b> , Cervantes A, Vermoken J. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). Int J Gynecol Cancer. 2011 Feb;21(2):419-23. IF: 1.733	N/A
10.	<b>Sjoquist, KM, Martyn JK</b> , Edmondson RJ, <b>Friedlander ML</b> , The role of hormonal therapy in gynecological cancers-current status and future directions.. Int J Gynecol Cancer. 2011 Oct;21(7): 1328-33. IF: 1.733	PARAGON
11.	Stuart GC, Kitchener H, Bacon M, Dubois A, <b>Friedlander M</b> , Ledermann J, Marth C, Thigpen T, Trimble E. 2010 Gynecologic Cancer InterGroup (GCIg) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011 May;21(4):750-5. IF: 1.733	N/A
12.	Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, <b>Quinn M</b> , Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC. First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer. 2011 May;21(4):756-62. IF: 1.733	N/A
<b>2010</b>		
1.	<b>Friedlander M</b> , editor. Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer. American Society of Clinical Oncology; 2010; Chicago, IL.	Symptom Benefit
2.	<b>Friedlander M</b> . Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy? Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S20-3. IF: 1.733	TRIPOD
3.	<b>Friedlander M</b> . Symptom Benefit and Symptom Control in Patients with Recurrent Ovarian Cancer. In: Poveda A, editor. 100 Key Questions in Ovarian Cancer: Permaneyer Publications; 2010. p. 91-101.	Symptom Benefit
4.	<b>Gainford MC</b> , Tinker A, <b>Carter J</b> , Petru E, <b>Nicklin J</b> , <b>Quinn M</b> , <b>Hammond I</b> , Elit L, Lenhard M, <b>Friedlander M</b> . Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIg) study. Int J Gynecol Cancer. 2010 Jan;20(1):75-81.	N/A
5.	<b>Quinn M</b> . Progress in ovarian cancer trials: the GCIg consensus model--is bigger, better? Gynecol Oncol. 2010 Oct;119(1):5-6.	N/A
6.	Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, <b>GebSKI V</b> , Heywood M, <b>Vasey PA</b> , et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9.	CALYPSO
<b>2009</b>		
1.	Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, <b>Friedlander M</b> , Colombo N, Fowler JM, Argenta PA, de Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.	GOG182
2.	<b>Friedlander M</b> , <b>Butow P</b> , <b>Stockler M</b> , <b>Gainford C</b> , <b>Martyn J</b> , Oza A, Donovan HS, Miller B, <b>King M</b> . Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S44-8.	Symptom Benefit
3.	Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, <b>Friedlander</b>	N/A

	<b>M</b> , Fujiwara K, Kaplan RS, Meunier F. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol. 2009 Oct 20;27(30):5109-14.	
<b>2008</b>		
1.	Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. (GOG 199 study, ANZGOG acknowledgement)	GOG199
<b>2007</b>		
1.	Gaffney DK, Du Bois A, <b>Narayan K</b> , Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble EL. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIg). Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):485-90.	N/A
2.	<b>Tinker AV, GebSKI V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D.</b> Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Gynecol Oncol. 2007 Mar;104(3):647-53.	ANZGOG020 1
<b>2005</b>		
1.	du Bois A, <b>Quinn M</b> , Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer, E, <b>Friedlander M</b> , Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, <b>Vasey P</b> , Vergote I, Verheijen R, Wagner U. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIg OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.	N/A
2.	<b>Quinn M</b> , Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J. History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. Ann Oncol. 2005;16 Suppl 8:viii5-viii6.	N/A
3.	<b>Quinn M</b> , Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, <b>Vasey P</b> , Wagner U. Integration of new or experimental treatment options and new approaches to clinical trials. Ann Oncol. 2005;16 Suppl 8:viii30-viii5.	N/A
4.	Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, <b>Friedlander M</b> , Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, <b>Quinn M</b> , Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, <b>Vasey P</b> , Vergote I, Verheijen R, Vermoken J, Wagner U. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol. 2005;16 Suppl 8:viii36-viii8.	N/A